4th Nasal Formulation and Delivery Summit

The 4th Nasal Formulation and Delivery Summit is uniting formulation, delivery, and product development leaders from across pharma and biotech to advance the development of safe, effective, and commercially viable intranasal therapies. As intranasal delivery gains validation across systemic, CNS, and emergency-use indications, the pressure to optimize formulations, align drug–device strategies, and generate predictive preclinical and clinical data has never been greater.
 
In an era of accelerating approvals, expanding modalities, and heightened regulatory scrutiny, teams must move beyond proof-of-concept to ensure intranasal programs are scalable, translatable, and fit for commercialization. Success now depends on solving formulation and delivery challenges early, while designing development strategies that withstand clinical, regulatory, and manufacturing demands.
 
This year, join 70+ experts from Eli Lilly, Bayer, Neurelis, Virpax Pharmaceuticals, Belhaven Biopharma, and more to explore real-world preclinical and clinical data, compare liquid and powder nasal approaches, and align on best practices for systemic and nose-to-brain delivery. Don't miss the only industry-led meeting dedicated exclusively to end-to-end intranasal formulation, delivery, and commercialization.